title: In vitro trials of some antimicrobial combinations against Staphylococcus aureus and Pseudomonas aeruginosa.
abstract: Staphylococcus aureus and Pseudomonas aeruginosa are rapidly increasing as multidrug resistant strains worldwide. In nosocomial settings because of heavy exposure of different antimicrobials, resistance in these pathogens turned into a grave issue in both developed and developing countries. The aim of this study was to investigate in vitro antibiotic synergism of combinations of β-lactam-β-lactam and β-lactam-aminoglycoside against clinical isolates of S. aureus and P. aeruginosa. Synergy was determined by checkerboard double dilution method. The combination of amoxicillin and cefadroxil was found to be synergistic against 47 S. aureus isolates, in the FICI range of 0.14-0.50 (81.03%) followed by the combination of streptomycin and cefadroxil synergistic against 44 S. aureus isolates in the FICI range of 0.03-0.50 (75.86%). The combination of streptomycin and cefadroxil was observed to be synergistic against 39 P. aeruginosa isolates in the FICI range of 0.16-0.50 (81.28%). Further actions are needed to characterize the possible interaction mechanism between these antibiotics. Moreover, the combination of streptomycin and cefadroxil may lead to the development of a new and vital antimicrobial against simultaneous infections of S. aureus and P. aeruginosa.
authors: Department of Microbiology, Saifia P.G. College of Science and Education, Bhopal 462001, India.
authors: Zafar
authors: Z
authors: Ahmed
authors: Shaukat
authors: S
authors: Saeed Khan
authors: Mahnaaz
authors: M
authors: Khan
keywords: Antimicrobial; FICI, fractional inhibitory concentration index; MIC, minimum inhibitory concentration; MRSA, methicillin resistant Staphylococcus aureus; P. aeruginosa; S. aureus; Synergism
references: Chemotherapy. 1998 Sep;44 Suppl 1:6-9
references: 9797416
references: Am J Clin Pathol. 1966 Apr;45(4):493-6
references: 5325707
references: Antimicrob Agents Chemother. 2001 Dec;45(12):3328-33
references: 11709304
references: Diagn Microbiol Infect Dis. 1998 Jun;31(2):373-6
references: 9635912
references: Antibiot Chemother (1971). 1989;42:257-63
references: 2512840
references: Open Microbiol J. 2008;2:79-84
references: 19088915
references: Postgrad Med. 2005 Jan;117(1):41-8
references: 15672890
references: Jpn J Antibiot. 1996 Aug;49(8):782-99
references: 9053533
references: J Antibiot (Tokyo). 2007 May;60(5):335-8
references: 17551215
references: Jpn J Antibiot. 1991 Nov;44(11):1211-5
references: 1664469
references: Curr Infect Dis Rep. 2001 Dec;3(6):487-495
references: 11722804
references: N Engl J Med. 2003 Feb 13;348(7):651-6
references: 12584377
references: Int J Antimicrob Agents. 2006 Feb;27(2):87-96
references: 16423509
references: J Chemother. 2004 Aug;16(4):400-3
references: 15332717
references: Indian J Med Microbiol. 2004 Jul-Sep;22(3):182-4
references: 17642729
references: Eur J Clin Microbiol. 1987 Aug;6(4):439-45
references: 3311738
references: Am J Med. 1986 May 30;80(5C):21-9
references: 3487247
references: Med Lab Sci. 1986 Apr;43(2):196-8
references: 3526074